Evidence map›Paper›PMID 38831604›Full record

ArticleJournal of cosmetic dermatology2024

Topical moisturizer with rose stem cell-derived exosomes (RSCEs) for recalcitrant seborrheic dermatitis: A case report with 6 months of follow-up.

Suparuj Lueangarun, Byong Seung Cho, Therdpong Tempark

Registry-linked trialAbstract readCase Reports
In one paragraph

Article in Journal of cosmetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07372001 (Effects on Facial Skin Aging After Topical Application of Exosomes With a Microneedling Device), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07372001 phase4completednot on this map

Effects on Facial Skin Aging After Topical Application of Exosomes With a Microneedling Device

TypeinterventionalSponsorInstituto de Oftalmología Fundación Conde de ValencianaRan2024 to 2025Enrolled30ConditionsSkin AgingArmsTopical lyophilized exosomes application
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Biogenesis of Au Nanoparticles from Plant-Derived Metabolites -ACS biomaterials science & engineering · 2026
    Article
  3. Article
  4. Article
  5. Application of StandardizedPharmaceutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Suparuj LueangarunDepartment of Aesthetic Medicine, College of Integrative Medicine, Dhurakij Pundit University, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-8121-2982
Byong Seung ChoExoCoBio Exosome Institute (EEI), ExoCoBio Inc., Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-5666-2666
Therdpong TemparkDepartment of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Pathum Wan, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5645-2135

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeborrheic dermatitis (SD) poses significant treatment challenges due to its chronic nature and the side effects associated with long-term use of conventional therapies like topical corticosteroids. In the search for alternative treatments, exosomes, particularly those derived from rose stem cells (RSCEs), offer a promising avenue due to their potential in managing chronic skin conditions.

objectiveThis case report examines the efficacy of a topical moisturizer containing RSCEs in treating a patient with refractory SD, aiming to provide an alternative treatment pathway. MATERIALS AND

methodsA 40-year-old male with a long-standing history of SD, unresponsive to traditional treatments, underwent a novel treatment regimen. This regimen included an initial topical application of 2.5 mL of RSCEs followed by a maintenance phase involving the application of a RSCE-containing moisturizer. Clinical outcomes were assessed through the Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) scores, along with evaluations of scaling and erythema.

resultsRemarkable clinical improvement was noted as early as 1-day post-treatment, with significant reductions in redness, scaling, and itching. The patient experienced sustained relief throughout the 6-month follow-up, with a recurrence in the sixth month that was less severe than previous flare-ups. This demonstrated not only the efficacy of RSCEs in symptom management but also their potential in extending remission periods.

conclusionThe chronic management of SD can benefit from innovative treatments like the RSCE-containing moisturizer, as shown in this case report. While the observed outcomes are promising, indicating substantial improvements in skin condition and symptom management, larger controlled studies are necessary to validate the therapeutic potential of exosome-containing moisturizers fully. This case underscores the need for alternative therapies in SD treatment, highlighting the role of exosomes as a viable option.

Indexed as

Dermatitis, SeborrheicExosomesAdministration, CutaneousAdultFollow-Up StudiesHumansMaleSkin CreamStem CellsTreatment Outcomeexosomesinflammatory skin conditionmoisturizerseborrheic dermatitistopical treatment

Identifiers

PMID38831604
PMCPMC13649084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.